224 related articles for article (PubMed ID: 29120964)
1. Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016.
Brzozowska M; Wierzba W; Śliwczyński A; Świerkowski M; Potemski P; Marczak M
Melanoma Res; 2018 Feb; 28(1):52-55. PubMed ID: 29120964
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.
Lang BM; Peveling-Oberhag A; Faidt D; Hötker AM; Weyer-Elberich V; Grabbe S; Loquai C
Med Oncol; 2018 Jan; 35(3):24. PubMed ID: 29387968
[TBL] [Abstract][Full Text] [Related]
3. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data.
Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Wysoczański W; Matusewicz W; Kozłowska-Wojciechowska M
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2087-2094. PubMed ID: 28608286
[TBL] [Abstract][Full Text] [Related]
4. Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib.
Enewold L; Sharon E; Harlan LC
Oncol Res Treat; 2017; 40(4):174-183. PubMed ID: 28376479
[TBL] [Abstract][Full Text] [Related]
5. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
6. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data.
Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Kozłowska-Wojciechowska M
Eur J Clin Pharmacol; 2019 Mar; 75(3):329-334. PubMed ID: 30386910
[TBL] [Abstract][Full Text] [Related]
9. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
[TBL] [Abstract][Full Text] [Related]
10. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
11. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
12. The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison.
Galván-Banqueri M; Ubago-Pérez R; Molina-López T
J Clin Pharm Ther; 2016 Jun; 41(3):285-9. PubMed ID: 27079278
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
[No Abstract] [Full Text] [Related]
16. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
17. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
[TBL] [Abstract][Full Text] [Related]
18. Targeting brain metastases in patients with melanoma.
Papadatos-Pastos D; Soultati A; Harries M
Biomed Res Int; 2013; 2013():186563. PubMed ID: 24455677
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
